Last reviewed · How we verify
S-1, Irinotecan, Bevacizumab
At a glance
| Generic name | S-1, Irinotecan, Bevacizumab |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer (PHASE1)
- Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer (PHASE2)
- S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery (PHASE2)
- Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer (PHASE2)
- Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-1, Irinotecan, Bevacizumab CI brief — competitive landscape report
- S-1, Irinotecan, Bevacizumab updates RSS · CI watch RSS
- Taiho Pharmaceutical Co., Ltd. portfolio CI